<?xml version="1.0" encoding="UTF-8"?>
<billStatus>
  <bill>
    <committees>
      <billCommittees>
        <item>
          <subcommittees>
            <item>
              <systemCode>hsif14</systemCode>
              <activities>
                <item>
                  <date>2016-02-19T14:38:54Z</date>
                  <name>Referred to</name>
                </item>
              </activities>
              <name>Health Subcommittee</name>
            </item>
          </subcommittees>
          <activities>
            <item>
              <date>2016-02-12T14:01:40Z</date>
              <name>Referred to</name>
            </item>
          </activities>
          <type>Standing</type>
          <systemCode>hsif00</systemCode>
          <chamber>House</chamber>
          <name>Energy and Commerce Committee</name>
        </item>
      </billCommittees>
    </committees>
    <congress>114</congress>
    <billNumber>4565</billNumber>
    <updateDate>2016-11-02T22:37:22Z</updateDate>
    <subjects>
      <billSubjects>
        <policyArea>
          <name>Health</name>
        </policyArea>
        <legislativeSubjects>
          <item>
            <name>Drug safety, medical device, and laboratory regulation</name>
          </item>
          <item>
            <name>Marketing and advertising</name>
          </item>
          <item>
            <name>Prescription drugs</name>
          </item>
        </legislativeSubjects>
      </billSubjects>
    </subjects>
    <policyArea>
      <name>Health</name>
    </policyArea>
    <summaries>
      <billSummaries>
        <item>
          <updateDate>2016-02-12T05:00:00Z</updateDate>
          <lastSummaryUpdateDate>2016-09-15T19:54:13Z</lastSummaryUpdateDate>
          <actionDate>2016-02-12</actionDate>
          <text><![CDATA[<p><b>Responsibility in Drug Advertising Act of 2016</b></p> This bill amends the Federal Food, Drug, and Cosmetic Act to prohibit direct-to-consumer advertising of a drug in the first three years after the drug's approval. The Food and Drug Administration may: (1) waive the third year of this prohibition for a drug if direct-to-consumer advertising of the drug would have an affirmative value to public health, or (2) extend the prohibition if the drug has significant adverse health effects.]]></text>
          <name>Introduced in House</name>
          <versionCode>00</versionCode>
          <actionDesc>Introduced in House</actionDesc>
        </item>
      </billSummaries>
    </summaries>
    <title>Responsibility in Drug Advertising Act of 2016</title>
    <laws />
    <cosponsors />
    <billType>HR</billType>
    <cboCostEstimates />
    <recordedVotes />
    <relatedBills />
    <actions>
      <actionByCounts>
        <houseOfRepresentatives>4</houseOfRepresentatives>
      </actionByCounts>
      <item>
        <actionDate>2016-02-19</actionDate>
        <committee>
          <name>Health Subcommittee</name>
          <systemCode>hsif14</systemCode>
        </committee>
        <links />
        <sourceSystem>
          <name>House committee actions</name>
          <code>1</code>
        </sourceSystem>
        <text>Referred to the Subcommittee on Health.</text>
        <type>Committee</type>
      </item>
      <item>
        <actionCode>H11100</actionCode>
        <links />
        <type>IntroReferral</type>
        <actionDate>2016-02-12</actionDate>
        <committee>
          <name>Energy and Commerce Committee</name>
          <systemCode>hsif00</systemCode>
        </committee>
        <text>Referred to the House Committee on Energy and Commerce.</text>
        <sourceSystem>
          <name>House floor actions</name>
          <code>2</code>
        </sourceSystem>
      </item>
      <item>
        <actionCode>Intro-H</actionCode>
        <links />
        <type>IntroReferral</type>
        <actionDate>2016-02-12</actionDate>
        <committee />
        <text>Introduced in House</text>
        <sourceSystem>
          <name>Library of Congress</name>
          <code>9</code>
        </sourceSystem>
      </item>
      <item>
        <actionCode>1000</actionCode>
        <links />
        <type>IntroReferral</type>
        <actionDate>2016-02-12</actionDate>
        <committee />
        <text>Introduced in House</text>
        <sourceSystem>
          <name>Library of Congress</name>
          <code>9</code>
        </sourceSystem>
      </item>
      <actionTypeCounts>
        <introducedInTheHouse>1</introducedInTheHouse>
        <billReferrals>1</billReferrals>
        <introducedInHouse>1</introducedInHouse>
        <placeholderTextForH>1</placeholderTextForH>
      </actionTypeCounts>
    </actions>
    <notes />
    <latestAction>
      <actionDate>2016-02-19</actionDate>
      <links />
      <text>Referred to the Subcommittee on Health.</text>
    </latestAction>
    <introducedDate>2016-02-12</introducedDate>
    <sponsors>
      <item>
        <fullName>Rep. DeLauro, Rosa L. [D-CT-3]</fullName>
        <firstName>ROSA</firstName>
        <byRequestType />
        <identifiers>
          <lisID>281</lisID>
          <gpoId>7868</gpoId>
          <bioguideId>D000216</bioguideId>
        </identifiers>
        <middleName />
        <bioguideId>D000216</bioguideId>
        <district>3</district>
        <party>D</party>
        <state>CT</state>
        <lastName>DELAURO</lastName>
      </item>
    </sponsors>
    <constitutionalAuthorityStatementText><![CDATA[<pre>From the Congressional Record Online through the Government Publishing Office [<a href='http://www.gpo.gov'>www.gpo.gov</a>]By Ms. DeLAURO:H.R. 4565.Congress has the power to enact this legislation pursuantto the following:Article 1, Section 8, Clauses 3 and 18 of the United StatesCongress[Page H818]</pre>]]></constitutionalAuthorityStatementText>
    <calendarNumbers />
    <committeeReports />
    <amendments />
    <createDate>2016-02-13T04:46:35Z</createDate>
    <originChamber>House</originChamber>
    <titles>
      <item>
        <title>Responsibility in Drug Advertising Act of 2016</title>
        <chamberCode />
        <chamberName />
        <titleType>Short Titles as Introduced</titleType>
        <parentTitleType />
      </item>
      <item>
        <title>To amend the Federal Food, Drug, and Cosmetic Act to restrict direct-to-consumer drug advertising.</title>
        <chamberCode />
        <chamberName />
        <titleType>Official Title as Introduced</titleType>
        <parentTitleType />
      </item>
      <item>
        <title>Responsibility in Drug Advertising Act of 2016</title>
        <chamberCode />
        <chamberName />
        <titleType>Display Title</titleType>
        <parentTitleType />
      </item>
    </titles>
  </bill>
  <dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
    <dc:format>text/xml</dc:format>
    <dc:language>EN</dc:language>
    <dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
    <dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
    <dc:description>This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
  </dublinCore>
</billStatus>

